Fungal infections

Infections in Medicine

Volumn 20, Issue 9, 2003, Pages 424-436

  Kauffman, Carol A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Aspergillus; Blastomyces; Candida; Cryptococcus; Fusarium; Infection, fungal; Trichosporon

Indexed keywords

AMPHOTERICIN B; ANTACID AGENT; ANTIFUNGAL AGENT; CASPOFUNGIN; CREATININE; CYCLODEXTRIN DERIVATIVE; DEFEROXAMINE; ECHINOCANDIN B DERIVATIVE; FLUCONAZOLE; FLUCYTOSINE; HISTAMINE H2 RECEPTOR ANTAGONIST; IRON; IRON CHELATING AGENT; ITRACONAZOLE; PROTON PUMP INHIBITOR; PYRROLE DERIVATIVE; VORICONAZOLE;

ALOPECIA; ARTICLE; ASPERGILLOSIS; BLASTOMYCOSIS; BONE MARROW TOXICITY; CANDIDIASIS; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; COMPUTER ASSISTED TOMOGRAPHY; CRYPTOCOCCOSIS; DEBRIDEMENT; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; EDEMA; ENDEMIC DISEASE; FACE PAIN; FATALITY; FUNGAL MENINGITIS; FUNGUS GROWTH; HEART DISEASE; HISTOPLASMOSIS; HUMAN; HYPOKALEMIA; IMMUNE DEFICIENCY; INDIVIDUALIZATION; INTRACRANIAL PRESSURE; KIDNEY FAILURE; LIVER DISEASE; LUNG INJURY; MORTALITY; MUCORMYCOSIS; MYCOSIS; NEPHROTOXICITY; NONHUMAN; OPPORTUNISTIC INFECTION; PREGNANCY; RICKETTSIOSIS; SINUSITIS; SKIN DEFECT; SKIN DISEASE; SKIN NODULE; THORAX RADIOGRAPHY;

EID: 0141729281     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Cano MV, Hajjeh RA. The epidemiology of histoplasmosis: a review. Semin Respir Infect. 2001;16:109-118.
2. Cairns L, Blythe D, Kao A, et al. Outbreak of coccidioidomycosis in Washington state residents returning from Mexico. Clin Infect Dis. 2000;30:61-64.
3. Mardo D, Christensen RA, Nielson N, et al. Coccidioidomycosis in workers at an archeological site - Dinosaur National Monument, Utah, June-July 2001. MMWR. 2001;50:1005-1008.
4. Johnson JE, Kabler JD, Gourley MF, et al. Cave-associated histoplasmosis - Costa Rica. MMWR. 1988;37:312-313.
5. Wheat LJ. Laboratory diagnosis of histoplasmosis: update 2000. Semin Respir Infect. 2001; 16:131-140.
6. Sheflin JR, Campbell JA, Thompson GP. Pulmonary blastomycosis: findings on chest radiographs in 63 patients. AJR. 1990;154:1177-1180.
7. Areno JP, Campbell GD Jr, George RB. Diagnosis of blastomycosis. Semin Respir Infect. 1997; 12:252-262.
8. Reed KD, Moore FM, Geiger G, Stemper ME. Zoonotic transmission of sporotrichosis: case report and review. Clin Infect Dis. 1993;16:384-387.
9. Kauffman CA. Sporotrichosis: state-of-the-art review. Clin Infect Dis. 1999;29:231-237.
10. Mahal M, Saiman L, Bitman L, et al. Review of trichosporonosis with a report of a case of disseminated Trichosporon asahii infection. Infect Dis Clin Pract. 1998;7:175-179.
11. Erer B, Galimberti M, Lucarelli G, et al. Trichosporon beigelii: a life-threatening pathogen in immunocompromised hosts. Bone Marrow Transplant. 2000;25:745-749.
12. Fleming RV, Walsh TJ, Anaissie EJ. Emerging and less common fungal pathogens. Infect Dis Clin North Am. 2002;16:915-933.
13. Daly AL, Velazquez LA, Bradley SF, Kauffman CA. Mucormycosis: association with deferoxamine therapy Am J Med. 1989;87:468-471.
14. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis. 2000;30:851-856.
15. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev. 2000;13:236-301.
16. Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:909-917.
17. Castiglioni B, Sutton DA, Rinaldi MG, et al. Pseudallescheria boydii (anamorph Scedosporium apiospermum) infection in solid organ transplant recipients in a tertiary medical center and review of the literature. Medicine (Baltimore). 2002;81:333-348.
18. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood. 1997;90:999-1008.
19. Anaissie EJ, Kuchar RT, Rex JH, et al. Fusariosis associated with pathogenic Fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis. 2001;33:1871-1878.
20. Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis. 2002;35:909-920.
21. Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol. 1997;15:139-147.
22. Caillot D, Couaillier JF, Benard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol. 2001;19: 253-259.
23. Thaler M, Pastakia B, Shawker TH, et al. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med. 1988;108:88-100.
24. Anttila VJ, Elonen E, Nordling S, et al. Hepatosplenic candidiasis in patients with acute leukemia: incidence and prognostic implications. Clin Infect Dis. 1997;24:375-180.
25. Malani PN, Kauffman CA. Invasive and allergic fungal sinusitis. Curr Infect Dis Rep. 2002;4: 225-232.
26. Iwen PC, Rupp ME, Hinrichs SH. Invasive mold sinusitis: 17 cases in immunocompromised patients and review of the literature. Clin Infect Dis. 1997;24:1178-1184.
27. Gillespie MB, O'Malley BW Jr, Francis HW. An approach to fulminant invasive fungal rhinosinusitis in the immunocompromised host. Arch Otolaryngol Head Neck Surg. 1998;124:520-526.
28. Galgiani JN, Ampel NM, Catanzaro A, et al. Practice guidelines for the treatment of coccidioidomycosis. Clin Infect Dis. 2000;30:658-661.
29. Stevens DA, Shatsky SA. Intrathecal amphotericin B in the management of coccidioidal meningitis. Semin Respir Infect. 2001;16:263-269.
30. Dewsnup DH, Galgiani JN, Graybill JR, et al. Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann Intern Med. 1996;124: 305-310.
31. van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med. 1997;337:15-21.
32. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis. 2000;30:710-718.
33. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med. 1992;326:83-89.
34. Pappas PG, Perfect JP, Cloud CA, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis. 2001;33:690-699.
35. Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. Clin Infect Dis. 2000;30:47-54.
36. Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis. 1999;29:239-244.
37. Blumberg HM, Jarvis WR, Soucie JM, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study Clin Infect Dis. 2001;33:177-186.
38. Nucci M, Anaissie E. Should vascular catheters be removed from all patients with candidemia? An evidence-based review. Clin Infect Dis. 2002; 34:591-599.
39. Edwards JE Jr, Bodey GP, Bowden RA, et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis. 1997;25:43-59.
40. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis. 2000;20:662-678.
41. Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis. 2002;35:359-366.
42. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-415.
43. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis. 2003;36:1445-1457.
44. Pursley TJ, Blomquist IK, Abraham J, et al. Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis. 1996;22:336-340.
45. Kauffman CA, Carver PL. Use of azoles for systemic antifungal therapy. Adv Pharmacol. 1997; 39:143-189.
46. Barone JA, Moskovitz BL, Guarnieri J, et al. Enhanced bioavailability of itraconazole in hydroxypropyl-β-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother. 1998;42:1862-1865.
47. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003;36:630-637.
48. Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet. 2001;357:1766-1767.
49. Pappas PG, Kauffman CA, Perfect J, et al. Alopecia associated with fluconazole therapy. Ann Intern Med. 1995;123:354-357.
50. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346:225-234.
51. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347: 2020-2029.